4 completed, 3 terminated, 2 unknown, 1 active not recruiting. 10 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Terminated 3, Unknown 2, Active not recruiting 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Antiemetics: new trials by email Literature Review of Antiemetics trials Research Report on Antiemetics
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) MK-1200, Antiemetic - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 13 | 2024-02-28 | 2026-06-05 |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer Oxaliplatin and capecitabine, Total Mesorectal Excision - Rectal Cancer | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 119 | 2019-03-01 | 2020-03-05 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Selinexor, Melphalan, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2017-07-20 | 2022-11-04 |
| Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs Satoreotide tetraxetan, Amino acid solution, Antiemetic - Neuroendocrine Tumors | Phase 1 / Phase 2 | Terminated | Ipsen | 40 | 2017-03-06 | 2023-07-19 |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) Cabazitaxel, Antihistamine, Corticosteroid - Circulating Tumor Cell, Metastatic Prostate Cancer | Phase 2 | Unknown | Erasmus Medical Center | 140 | 2017-02-21 | 2021-08-20 |
| Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin) - Non-small Cell Lung Cancer, Postmenopausal Women | Phase 2 | Terminated | University of Pittsburgh | 3 | 2010-09-01 | 2017-10-19 |
| A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas Perifosine, Loperamide, Allopurinol - Chondrosarcomas, Alveolar Soft Part Sarcomas | Phase 2 | Completed | AEterna Zentaris | 72 | 2006-11-01 | 2018-03-07 |
Multiple Myeloma (2) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Non-Small-Cell Lung (1) · Chondrosarcoma (1) · Ependymoma (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma (1) · Medulloblastoma (1) · Neoplastic Cells, Circulating (1) · Neuroendocrine Tumors (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1) · Recurrence (1) · Sarcoma, Alveolar Soft Part (1)
National Cancer Institute (NCI) (2) · AEterna Zentaris (1) · Erasmus Medical Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Ipsen (1) · Merck Sharp & Dohme LLC (1) · Pediatric Brain Tumor Consortium (1) · Peking University Cancer Hospital & Institute (1) · University of Pittsburgh (1)
United States (7) · Australia (2) · China (2) · Austria (1) · Canada (1) · Chile (1) · Denmark (1) · France (1) · Israel (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Ahmad Tarhini, MD (1) · Aiwen Wu (1) · Dejka Araujo, MD (1) · James Gulley, M.D. (1) · Kevin C Conlon, M.D. (1) · Matthias Karajannis, MD, MS (1) · Taiga Nishihori, M.D. (1)
PMID 33023948, PMID 37721581, PMID 38528164
2015 (1), 2023 (1), UM1CA081457 (1)